nodes	percent_of_prediction	percent_of_DWPC	metapath
Vilazodone—CYP2D6—breast cancer	0.205	0.538	CbGaD
Vilazodone—CYP3A4—breast cancer	0.176	0.462	CbGaD
Vilazodone—CYP3A4—Exemestane—breast cancer	0.0399	0.103	CbGbCtD
Vilazodone—CYP2D6—Idarubicin—breast cancer	0.0361	0.093	CbGbCtD
Vilazodone—CYP3A4—Letrozole—breast cancer	0.034	0.0876	CbGbCtD
Vilazodone—CYP3A4—Anastrozole—breast cancer	0.0303	0.0781	CbGbCtD
Vilazodone—CYP3A4—Toremifene—breast cancer	0.0277	0.0714	CbGbCtD
Vilazodone—CYP3A4—Fulvestrant—breast cancer	0.0257	0.0664	CbGbCtD
Vilazodone—CYP3A4—Thiotepa—breast cancer	0.0229	0.0592	CbGbCtD
Vilazodone—CYP3A4—Ixabepilone—breast cancer	0.021	0.0541	CbGbCtD
Vilazodone—CYP3A4—Lapatinib—breast cancer	0.0202	0.0521	CbGbCtD
Vilazodone—CYP2D6—Vinorelbine—breast cancer	0.0176	0.0454	CbGbCtD
Vilazodone—CYP2D6—Tamoxifen—breast cancer	0.0159	0.041	CbGbCtD
Vilazodone—CYP3A4—Raloxifene—breast cancer	0.0153	0.0395	CbGbCtD
Vilazodone—CYP3A4—Vinorelbine—breast cancer	0.0112	0.0289	CbGbCtD
Vilazodone—CYP2D6—Vinblastine—breast cancer	0.0109	0.028	CbGbCtD
Vilazodone—CYP3A4—Tamoxifen—breast cancer	0.0101	0.0261	CbGbCtD
Vilazodone—CYP3A4—Mitoxantrone—breast cancer	0.00986	0.0254	CbGbCtD
Vilazodone—CYP3A4—Paclitaxel—breast cancer	0.00787	0.0203	CbGbCtD
Vilazodone—CYP3A4—Irinotecan—breast cancer	0.00776	0.02	CbGbCtD
Vilazodone—CYP3A4—Vinblastine—breast cancer	0.0069	0.0178	CbGbCtD
Vilazodone—CYP2D6—Doxorubicin—breast cancer	0.00667	0.0172	CbGbCtD
Vilazodone—CYP3A4—Docetaxel—breast cancer	0.00569	0.0147	CbGbCtD
Vilazodone—CYP3A4—Doxorubicin—breast cancer	0.00424	0.0109	CbGbCtD
Vilazodone—Aripiprazole—CYP2D6—breast cancer	0.000249	0.195	CrCbGaD
Vilazodone—Trazodone—CYP2D6—breast cancer	0.000248	0.194	CrCbGaD
Vilazodone—Aripiprazole—CYP3A4—breast cancer	0.000214	0.167	CrCbGaD
Vilazodone—Trazodone—CYP3A4—breast cancer	0.000213	0.166	CrCbGaD
Vilazodone—Aripiprazole—ABCB1—breast cancer	0.000178	0.139	CrCbGaD
Vilazodone—Trazodone—ABCB1—breast cancer	0.000177	0.139	CrCbGaD
Vilazodone—Hyperhidrosis—Gemcitabine—breast cancer	0.000164	0.00103	CcSEcCtD
Vilazodone—Nervous system disorder—Fluorouracil—breast cancer	0.000164	0.00103	CcSEcCtD
Vilazodone—Dizziness—Tamoxifen—breast cancer	0.000164	0.00103	CcSEcCtD
Vilazodone—Tremor—Paclitaxel—breast cancer	0.000163	0.00102	CcSEcCtD
Vilazodone—Increased appetite—Doxorubicin—breast cancer	0.000163	0.00102	CcSEcCtD
Vilazodone—Migraine—Epirubicin—breast cancer	0.000163	0.00102	CcSEcCtD
Vilazodone—Vomiting—Vinblastine—breast cancer	0.000162	0.00101	CcSEcCtD
Vilazodone—Diarrhoea—Goserelin—breast cancer	0.000162	0.00101	CcSEcCtD
Vilazodone—Connective tissue disorder—Capecitabine—breast cancer	0.000162	0.00101	CcSEcCtD
Vilazodone—Agitation—Paclitaxel—breast cancer	0.00016	0.001	CcSEcCtD
Vilazodone—Breast disorder—Methotrexate—breast cancer	0.00016	0.001	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Mitoxantrone—breast cancer	0.000159	0.000997	CcSEcCtD
Vilazodone—Eye disorder—Docetaxel—breast cancer	0.000159	0.000995	CcSEcCtD
Vilazodone—Insomnia—Irinotecan—breast cancer	0.000158	0.000989	CcSEcCtD
Vilazodone—Cardiac disorder—Docetaxel—breast cancer	0.000158	0.000988	CcSEcCtD
Vilazodone—Vomiting—Tamoxifen—breast cancer	0.000157	0.000986	CcSEcCtD
Vilazodone—Paraesthesia—Irinotecan—breast cancer	0.000157	0.000982	CcSEcCtD
Vilazodone—Paraesthesia—Mitoxantrone—breast cancer	0.000157	0.000982	CcSEcCtD
Vilazodone—Dizziness—Goserelin—breast cancer	0.000156	0.000979	CcSEcCtD
Vilazodone—Somnolence—Mitoxantrone—breast cancer	0.000155	0.000973	CcSEcCtD
Vilazodone—Somnolence—Irinotecan—breast cancer	0.000155	0.000973	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Gemcitabine—breast cancer	0.000155	0.000971	CcSEcCtD
Vilazodone—Palpitations—Paclitaxel—breast cancer	0.000154	0.000966	CcSEcCtD
Vilazodone—Vomiting—Melphalan—breast cancer	0.000154	0.000965	CcSEcCtD
Vilazodone—Hyponatraemia—Doxorubicin—breast cancer	0.000154	0.000964	CcSEcCtD
Vilazodone—Insomnia—Gemcitabine—breast cancer	0.000154	0.000964	CcSEcCtD
Vilazodone—Eye disorder—Capecitabine—breast cancer	0.000154	0.000963	CcSEcCtD
Vilazodone—Dyspepsia—Irinotecan—breast cancer	0.000154	0.000963	CcSEcCtD
Vilazodone—Dyspepsia—Mitoxantrone—breast cancer	0.000154	0.000963	CcSEcCtD
Vilazodone—Paraesthesia—Gemcitabine—breast cancer	0.000153	0.000957	CcSEcCtD
Vilazodone—Cardiac disorder—Capecitabine—breast cancer	0.000153	0.000956	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Fluorouracil—breast cancer	0.000152	0.000955	CcSEcCtD
Vilazodone—Asthenia—Vinorelbine—breast cancer	0.000152	0.000952	CcSEcCtD
Vilazodone—Decreased appetite—Irinotecan—breast cancer	0.000152	0.000951	CcSEcCtD
Vilazodone—Decreased appetite—Mitoxantrone—breast cancer	0.000152	0.000951	CcSEcCtD
Vilazodone—Nausea—Vinblastine—breast cancer	0.000151	0.000948	CcSEcCtD
Vilazodone—Insomnia—Fluorouracil—breast cancer	0.000151	0.000948	CcSEcCtD
Vilazodone—Somnolence—Gemcitabine—breast cancer	0.000151	0.000947	CcSEcCtD
Vilazodone—Convulsion—Paclitaxel—breast cancer	0.000151	0.000947	CcSEcCtD
Vilazodone—Migraine—Doxorubicin—breast cancer	0.000151	0.000945	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Irinotecan—breast cancer	0.000151	0.000944	CcSEcCtD
Vilazodone—Fatigue—Mitoxantrone—breast cancer	0.00015	0.000943	CcSEcCtD
Vilazodone—Fatigue—Irinotecan—breast cancer	0.00015	0.000943	CcSEcCtD
Vilazodone—Vomiting—Goserelin—breast cancer	0.00015	0.000942	CcSEcCtD
Vilazodone—Paraesthesia—Fluorouracil—breast cancer	0.00015	0.000941	CcSEcCtD
Vilazodone—Breast disorder—Epirubicin—breast cancer	0.00015	0.000938	CcSEcCtD
Vilazodone—Mental disorder—Docetaxel—breast cancer	0.000149	0.000933	CcSEcCtD
Vilazodone—Somnolence—Fluorouracil—breast cancer	0.000149	0.000931	CcSEcCtD
Vilazodone—Arthralgia—Paclitaxel—breast cancer	0.000148	0.000931	CcSEcCtD
Vilazodone—Malnutrition—Docetaxel—breast cancer	0.000148	0.000927	CcSEcCtD
Vilazodone—Decreased appetite—Gemcitabine—breast cancer	0.000148	0.000926	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—breast cancer	0.000147	0.000924	CcSEcCtD
Vilazodone—Dyspepsia—Fluorouracil—breast cancer	0.000147	0.000922	CcSEcCtD
Vilazodone—Nausea—Tamoxifen—breast cancer	0.000147	0.000921	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Gemcitabine—breast cancer	0.000147	0.00092	CcSEcCtD
Vilazodone—Fatigue—Gemcitabine—breast cancer	0.000147	0.000919	CcSEcCtD
Vilazodone—Decreased appetite—Fluorouracil—breast cancer	0.000145	0.000911	CcSEcCtD
Vilazodone—Dry mouth—Paclitaxel—breast cancer	0.000145	0.00091	CcSEcCtD
Vilazodone—Asthenia—Thiotepa—breast cancer	0.000145	0.000909	CcSEcCtD
Vilazodone—Diarrhoea—Vinorelbine—breast cancer	0.000145	0.000908	CcSEcCtD
Vilazodone—Dysgeusia—Docetaxel—breast cancer	0.000145	0.000907	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Fluorouracil—breast cancer	0.000144	0.000905	CcSEcCtD
Vilazodone—Mental disorder—Capecitabine—breast cancer	0.000144	0.000903	CcSEcCtD
Vilazodone—Nausea—Melphalan—breast cancer	0.000144	0.000902	CcSEcCtD
Vilazodone—Feeling abnormal—Irinotecan—breast cancer	0.000144	0.000901	CcSEcCtD
Vilazodone—Feeling abnormal—Mitoxantrone—breast cancer	0.000144	0.000901	CcSEcCtD
Vilazodone—Malnutrition—Capecitabine—breast cancer	0.000143	0.000897	CcSEcCtD
Vilazodone—Flatulence—Capecitabine—breast cancer	0.000141	0.000884	CcSEcCtD
Vilazodone—Erectile dysfunction—Methotrexate—breast cancer	0.000141	0.000883	CcSEcCtD
Vilazodone—Nausea—Goserelin—breast cancer	0.00014	0.00088	CcSEcCtD
Vilazodone—Dysgeusia—Capecitabine—breast cancer	0.00014	0.000879	CcSEcCtD
Vilazodone—Feeling abnormal—Gemcitabine—breast cancer	0.00014	0.000878	CcSEcCtD
Vilazodone—Dizziness—Vinorelbine—breast cancer	0.00014	0.000877	CcSEcCtD
Vilazodone—Nervous system disorder—Paclitaxel—breast cancer	0.00014	0.000875	CcSEcCtD
Vilazodone—Breast disorder—Doxorubicin—breast cancer	0.000138	0.000868	CcSEcCtD
Vilazodone—Diarrhoea—Thiotepa—breast cancer	0.000138	0.000867	CcSEcCtD
Vilazodone—Skin disorder—Paclitaxel—breast cancer	0.000138	0.000867	CcSEcCtD
Vilazodone—Feeling abnormal—Fluorouracil—breast cancer	0.000138	0.000863	CcSEcCtD
Vilazodone—Hyperhidrosis—Paclitaxel—breast cancer	0.000138	0.000863	CcSEcCtD
Vilazodone—Vision blurred—Capecitabine—breast cancer	0.000135	0.000845	CcSEcCtD
Vilazodone—Vomiting—Vinorelbine—breast cancer	0.000135	0.000843	CcSEcCtD
Vilazodone—Tremor—Capecitabine—breast cancer	0.000134	0.000841	CcSEcCtD
Vilazodone—Dizziness—Thiotepa—breast cancer	0.000134	0.000838	CcSEcCtD
Vilazodone—Pollakiuria—Epirubicin—breast cancer	0.000132	0.000829	CcSEcCtD
Vilazodone—Palpitations—Docetaxel—breast cancer	0.000131	0.000819	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Paclitaxel—breast cancer	0.00013	0.000813	CcSEcCtD
Vilazodone—Insomnia—Paclitaxel—breast cancer	0.000129	0.000807	CcSEcCtD
Vilazodone—Vomiting—Thiotepa—breast cancer	0.000129	0.000805	CcSEcCtD
Vilazodone—Convulsion—Docetaxel—breast cancer	0.000128	0.000803	CcSEcCtD
Vilazodone—Paraesthesia—Paclitaxel—breast cancer	0.000128	0.000801	CcSEcCtD
Vilazodone—Somnolence—Paclitaxel—breast cancer	0.000127	0.000793	CcSEcCtD
Vilazodone—Palpitations—Capecitabine—breast cancer	0.000126	0.000793	CcSEcCtD
Vilazodone—Arthralgia—Docetaxel—breast cancer	0.000126	0.000789	CcSEcCtD
Vilazodone—Nausea—Vinorelbine—breast cancer	0.000126	0.000788	CcSEcCtD
Vilazodone—Dyspepsia—Paclitaxel—breast cancer	0.000125	0.000785	CcSEcCtD
Vilazodone—Asthenia—Irinotecan—breast cancer	0.000125	0.000785	CcSEcCtD
Vilazodone—Asthenia—Mitoxantrone—breast cancer	0.000125	0.000785	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	0.000125	0.000783	CcSEcCtD
Vilazodone—Decreased appetite—Paclitaxel—breast cancer	0.000124	0.000776	CcSEcCtD
Vilazodone—Dry mouth—Docetaxel—breast cancer	0.000123	0.000772	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Paclitaxel—breast cancer	0.000123	0.00077	CcSEcCtD
Vilazodone—Fatigue—Paclitaxel—breast cancer	0.000123	0.000769	CcSEcCtD
Vilazodone—Pollakiuria—Doxorubicin—breast cancer	0.000122	0.000767	CcSEcCtD
Vilazodone—Asthenia—Gemcitabine—breast cancer	0.000122	0.000765	CcSEcCtD
Vilazodone—Arthralgia—Capecitabine—breast cancer	0.000122	0.000764	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	0.000121	0.000759	CcSEcCtD
Vilazodone—Nausea—Thiotepa—breast cancer	0.00012	0.000752	CcSEcCtD
Vilazodone—Diarrhoea—Irinotecan—breast cancer	0.000119	0.000749	CcSEcCtD
Vilazodone—Diarrhoea—Mitoxantrone—breast cancer	0.000119	0.000749	CcSEcCtD
Vilazodone—Dry mouth—Capecitabine—breast cancer	0.000119	0.000747	CcSEcCtD
Vilazodone—Nervous system disorder—Docetaxel—breast cancer	0.000118	0.000742	CcSEcCtD
Vilazodone—Feeling abnormal—Paclitaxel—breast cancer	0.000117	0.000735	CcSEcCtD
Vilazodone—Skin disorder—Docetaxel—breast cancer	0.000117	0.000735	CcSEcCtD
Vilazodone—Diarrhoea—Gemcitabine—breast cancer	0.000116	0.000729	CcSEcCtD
Vilazodone—Dizziness—Irinotecan—breast cancer	0.000115	0.000723	CcSEcCtD
Vilazodone—Nervous system disorder—Capecitabine—breast cancer	0.000115	0.000718	CcSEcCtD
Vilazodone—Eye disorder—Methotrexate—breast cancer	0.000114	0.000717	CcSEcCtD
Vilazodone—Diarrhoea—Fluorouracil—breast cancer	0.000114	0.000717	CcSEcCtD
Vilazodone—Cardiac disorder—Methotrexate—breast cancer	0.000114	0.000712	CcSEcCtD
Vilazodone—Skin disorder—Capecitabine—breast cancer	0.000113	0.000711	CcSEcCtD
Vilazodone—Hyperhidrosis—Capecitabine—breast cancer	0.000113	0.000708	CcSEcCtD
Vilazodone—Connective tissue disorder—Epirubicin—breast cancer	0.000113	0.000706	CcSEcCtD
Vilazodone—Vomiting—Irinotecan—breast cancer	0.000111	0.000696	CcSEcCtD
Vilazodone—Vomiting—Mitoxantrone—breast cancer	0.000111	0.000696	CcSEcCtD
Vilazodone—Dizziness—Fluorouracil—breast cancer	0.000111	0.000693	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Docetaxel—breast cancer	0.00011	0.000689	CcSEcCtD
Vilazodone—Insomnia—Docetaxel—breast cancer	0.000109	0.000684	CcSEcCtD
Vilazodone—Paraesthesia—Docetaxel—breast cancer	0.000108	0.000679	CcSEcCtD
Vilazodone—Vomiting—Gemcitabine—breast cancer	0.000108	0.000678	CcSEcCtD
Vilazodone—Somnolence—Docetaxel—breast cancer	0.000107	0.000672	CcSEcCtD
Vilazodone—Mental disorder—Methotrexate—breast cancer	0.000107	0.000672	CcSEcCtD
Vilazodone—Eye disorder—Epirubicin—breast cancer	0.000107	0.000671	CcSEcCtD
Vilazodone—Malnutrition—Methotrexate—breast cancer	0.000107	0.000668	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Capecitabine—breast cancer	0.000106	0.000667	CcSEcCtD
Vilazodone—Cardiac disorder—Epirubicin—breast cancer	0.000106	0.000666	CcSEcCtD
Vilazodone—Vomiting—Fluorouracil—breast cancer	0.000106	0.000666	CcSEcCtD
Vilazodone—Dyspepsia—Docetaxel—breast cancer	0.000106	0.000666	CcSEcCtD
Vilazodone—Insomnia—Capecitabine—breast cancer	0.000106	0.000662	CcSEcCtD
Vilazodone—Paraesthesia—Capecitabine—breast cancer	0.000105	0.000657	CcSEcCtD
Vilazodone—Decreased appetite—Docetaxel—breast cancer	0.000105	0.000657	CcSEcCtD
Vilazodone—Dysgeusia—Methotrexate—breast cancer	0.000104	0.000654	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Docetaxel—breast cancer	0.000104	0.000653	CcSEcCtD
Vilazodone—Connective tissue disorder—Doxorubicin—breast cancer	0.000104	0.000653	CcSEcCtD
Vilazodone—Fatigue—Docetaxel—breast cancer	0.000104	0.000652	CcSEcCtD
Vilazodone—Nausea—Mitoxantrone—breast cancer	0.000104	0.00065	CcSEcCtD
Vilazodone—Nausea—Irinotecan—breast cancer	0.000104	0.00065	CcSEcCtD
Vilazodone—Dyspepsia—Capecitabine—breast cancer	0.000103	0.000645	CcSEcCtD
Vilazodone—Asthenia—Paclitaxel—breast cancer	0.000102	0.00064	CcSEcCtD
Vilazodone—Decreased appetite—Capecitabine—breast cancer	0.000102	0.000636	CcSEcCtD
Vilazodone—Nausea—Gemcitabine—breast cancer	0.000101	0.000633	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Capecitabine—breast cancer	0.000101	0.000632	CcSEcCtD
Vilazodone—Fatigue—Capecitabine—breast cancer	0.000101	0.000631	CcSEcCtD
Vilazodone—Vision blurred—Methotrexate—breast cancer	0.0001	0.000629	CcSEcCtD
Vilazodone—Mental disorder—Epirubicin—breast cancer	0.0001	0.000629	CcSEcCtD
Vilazodone—Malnutrition—Epirubicin—breast cancer	9.97e-05	0.000625	CcSEcCtD
Vilazodone—Feeling abnormal—Docetaxel—breast cancer	9.94e-05	0.000623	CcSEcCtD
Vilazodone—Nausea—Fluorouracil—breast cancer	9.93e-05	0.000622	CcSEcCtD
Vilazodone—Eye disorder—Doxorubicin—breast cancer	9.9e-05	0.000621	CcSEcCtD
Vilazodone—Cardiac disorder—Doxorubicin—breast cancer	9.84e-05	0.000617	CcSEcCtD
Vilazodone—Flatulence—Epirubicin—breast cancer	9.83e-05	0.000616	CcSEcCtD
Vilazodone—Dysgeusia—Epirubicin—breast cancer	9.76e-05	0.000612	CcSEcCtD
Vilazodone—Diarrhoea—Paclitaxel—breast cancer	9.74e-05	0.00061	CcSEcCtD
Vilazodone—Nervousness—Epirubicin—breast cancer	9.68e-05	0.000607	CcSEcCtD
Vilazodone—Feeling abnormal—Capecitabine—breast cancer	9.63e-05	0.000603	CcSEcCtD
Vilazodone—Dizziness—Paclitaxel—breast cancer	9.41e-05	0.00059	CcSEcCtD
Vilazodone—Vision blurred—Epirubicin—breast cancer	9.4e-05	0.000589	CcSEcCtD
Vilazodone—Mental disorder—Doxorubicin—breast cancer	9.29e-05	0.000582	CcSEcCtD
Vilazodone—Convulsion—Methotrexate—breast cancer	9.23e-05	0.000579	CcSEcCtD
Vilazodone—Malnutrition—Doxorubicin—breast cancer	9.23e-05	0.000578	CcSEcCtD
Vilazodone—Agitation—Epirubicin—breast cancer	9.16e-05	0.000574	CcSEcCtD
Vilazodone—Flatulence—Doxorubicin—breast cancer	9.09e-05	0.00057	CcSEcCtD
Vilazodone—Arthralgia—Methotrexate—breast cancer	9.07e-05	0.000569	CcSEcCtD
Vilazodone—Vomiting—Paclitaxel—breast cancer	9.05e-05	0.000567	CcSEcCtD
Vilazodone—Dysgeusia—Doxorubicin—breast cancer	9.04e-05	0.000566	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	9.01e-05	0.000565	CcSEcCtD
Vilazodone—Nervousness—Doxorubicin—breast cancer	8.96e-05	0.000562	CcSEcCtD
Vilazodone—Palpitations—Epirubicin—breast cancer	8.81e-05	0.000552	CcSEcCtD
Vilazodone—Vision blurred—Doxorubicin—breast cancer	8.7e-05	0.000545	CcSEcCtD
Vilazodone—Asthenia—Docetaxel—breast cancer	8.66e-05	0.000543	CcSEcCtD
Vilazodone—Convulsion—Epirubicin—breast cancer	8.64e-05	0.000542	CcSEcCtD
Vilazodone—Nervous system disorder—Methotrexate—breast cancer	8.53e-05	0.000535	CcSEcCtD
Vilazodone—Arthralgia—Epirubicin—breast cancer	8.49e-05	0.000532	CcSEcCtD
Vilazodone—Agitation—Doxorubicin—breast cancer	8.48e-05	0.000531	CcSEcCtD
Vilazodone—Nausea—Paclitaxel—breast cancer	8.46e-05	0.00053	CcSEcCtD
Vilazodone—Skin disorder—Methotrexate—breast cancer	8.45e-05	0.000529	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	8.43e-05	0.000528	CcSEcCtD
Vilazodone—Hyperhidrosis—Methotrexate—breast cancer	8.41e-05	0.000527	CcSEcCtD
Vilazodone—Asthenia—Capecitabine—breast cancer	8.38e-05	0.000525	CcSEcCtD
Vilazodone—Dry mouth—Epirubicin—breast cancer	8.3e-05	0.00052	CcSEcCtD
Vilazodone—Diarrhoea—Docetaxel—breast cancer	8.26e-05	0.000517	CcSEcCtD
Vilazodone—Palpitations—Doxorubicin—breast cancer	8.15e-05	0.000511	CcSEcCtD
Vilazodone—Convulsion—Doxorubicin—breast cancer	7.99e-05	0.000501	CcSEcCtD
Vilazodone—Diarrhoea—Capecitabine—breast cancer	7.99e-05	0.000501	CcSEcCtD
Vilazodone—Nervous system disorder—Epirubicin—breast cancer	7.98e-05	0.0005	CcSEcCtD
Vilazodone—Dizziness—Docetaxel—breast cancer	7.98e-05	0.0005	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Methotrexate—breast cancer	7.92e-05	0.000497	CcSEcCtD
Vilazodone—Skin disorder—Epirubicin—breast cancer	7.9e-05	0.000495	CcSEcCtD
Vilazodone—Hyperhidrosis—Epirubicin—breast cancer	7.87e-05	0.000493	CcSEcCtD
Vilazodone—Insomnia—Methotrexate—breast cancer	7.87e-05	0.000493	CcSEcCtD
Vilazodone—Arthralgia—Doxorubicin—breast cancer	7.85e-05	0.000492	CcSEcCtD
Vilazodone—Paraesthesia—Methotrexate—breast cancer	7.81e-05	0.000489	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	7.8e-05	0.000489	CcSEcCtD
Vilazodone—Somnolence—Methotrexate—breast cancer	7.73e-05	0.000485	CcSEcCtD
Vilazodone—Dizziness—Capecitabine—breast cancer	7.72e-05	0.000484	CcSEcCtD
Vilazodone—Dry mouth—Doxorubicin—breast cancer	7.68e-05	0.000481	CcSEcCtD
Vilazodone—Vomiting—Docetaxel—breast cancer	7.67e-05	0.000481	CcSEcCtD
Vilazodone—Dyspepsia—Methotrexate—breast cancer	7.65e-05	0.00048	CcSEcCtD
Vilazodone—Decreased appetite—Methotrexate—breast cancer	7.56e-05	0.000474	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Methotrexate—breast cancer	7.51e-05	0.000471	CcSEcCtD
Vilazodone—Fatigue—Methotrexate—breast cancer	7.5e-05	0.00047	CcSEcCtD
Vilazodone—Vomiting—Capecitabine—breast cancer	7.43e-05	0.000466	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Epirubicin—breast cancer	7.41e-05	0.000465	CcSEcCtD
Vilazodone—Nervous system disorder—Doxorubicin—breast cancer	7.38e-05	0.000463	CcSEcCtD
Vilazodone—Insomnia—Epirubicin—breast cancer	7.36e-05	0.000461	CcSEcCtD
Vilazodone—Skin disorder—Doxorubicin—breast cancer	7.31e-05	0.000458	CcSEcCtD
Vilazodone—Paraesthesia—Epirubicin—breast cancer	7.31e-05	0.000458	CcSEcCtD
Vilazodone—Hyperhidrosis—Doxorubicin—breast cancer	7.28e-05	0.000456	CcSEcCtD
Vilazodone—Somnolence—Epirubicin—breast cancer	7.23e-05	0.000453	CcSEcCtD
Vilazodone—Nausea—Docetaxel—breast cancer	7.17e-05	0.000449	CcSEcCtD
Vilazodone—Feeling abnormal—Methotrexate—breast cancer	7.17e-05	0.000449	CcSEcCtD
Vilazodone—Dyspepsia—Epirubicin—breast cancer	7.16e-05	0.000449	CcSEcCtD
Vilazodone—Decreased appetite—Epirubicin—breast cancer	7.07e-05	0.000443	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Epirubicin—breast cancer	7.03e-05	0.00044	CcSEcCtD
Vilazodone—Fatigue—Epirubicin—breast cancer	7.02e-05	0.00044	CcSEcCtD
Vilazodone—Nausea—Capecitabine—breast cancer	6.94e-05	0.000435	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Doxorubicin—breast cancer	6.86e-05	0.00043	CcSEcCtD
Vilazodone—Insomnia—Doxorubicin—breast cancer	6.81e-05	0.000427	CcSEcCtD
Vilazodone—Paraesthesia—Doxorubicin—breast cancer	6.76e-05	0.000424	CcSEcCtD
Vilazodone—Feeling abnormal—Epirubicin—breast cancer	6.71e-05	0.00042	CcSEcCtD
Vilazodone—Somnolence—Doxorubicin—breast cancer	6.69e-05	0.00042	CcSEcCtD
Vilazodone—Dyspepsia—Doxorubicin—breast cancer	6.63e-05	0.000415	CcSEcCtD
Vilazodone—Decreased appetite—Doxorubicin—breast cancer	6.55e-05	0.00041	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Doxorubicin—breast cancer	6.5e-05	0.000407	CcSEcCtD
Vilazodone—Fatigue—Doxorubicin—breast cancer	6.49e-05	0.000407	CcSEcCtD
Vilazodone—Asthenia—Methotrexate—breast cancer	6.24e-05	0.000391	CcSEcCtD
Vilazodone—Feeling abnormal—Doxorubicin—breast cancer	6.21e-05	0.000389	CcSEcCtD
Vilazodone—Diarrhoea—Methotrexate—breast cancer	5.95e-05	0.000373	CcSEcCtD
Vilazodone—Asthenia—Epirubicin—breast cancer	5.84e-05	0.000366	CcSEcCtD
Vilazodone—Dizziness—Methotrexate—breast cancer	5.75e-05	0.00036	CcSEcCtD
Vilazodone—Diarrhoea—Epirubicin—breast cancer	5.57e-05	0.000349	CcSEcCtD
Vilazodone—Vomiting—Methotrexate—breast cancer	5.53e-05	0.000347	CcSEcCtD
Vilazodone—Asthenia—Doxorubicin—breast cancer	5.4e-05	0.000339	CcSEcCtD
Vilazodone—Dizziness—Epirubicin—breast cancer	5.38e-05	0.000337	CcSEcCtD
Vilazodone—Vomiting—Epirubicin—breast cancer	5.17e-05	0.000324	CcSEcCtD
Vilazodone—Nausea—Methotrexate—breast cancer	5.17e-05	0.000324	CcSEcCtD
Vilazodone—Diarrhoea—Doxorubicin—breast cancer	5.15e-05	0.000323	CcSEcCtD
Vilazodone—Dizziness—Doxorubicin—breast cancer	4.98e-05	0.000312	CcSEcCtD
Vilazodone—Nausea—Epirubicin—breast cancer	4.83e-05	0.000303	CcSEcCtD
Vilazodone—Vomiting—Doxorubicin—breast cancer	4.79e-05	0.0003	CcSEcCtD
Vilazodone—Nausea—Doxorubicin—breast cancer	4.47e-05	0.00028	CcSEcCtD
Vilazodone—CYP3A4—Metabolism—GSTA3—breast cancer	7.78e-06	0.00011	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—HMMR—breast cancer	7.78e-06	0.00011	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ITPR1—breast cancer	7.67e-06	0.000109	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ERBB4—breast cancer	7.62e-06	0.000108	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—STAT5A—breast cancer	7.62e-06	0.000108	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MMP3—breast cancer	7.62e-06	0.000108	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—PIK3CB—breast cancer	7.6e-06	0.000108	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—SPP1—breast cancer	7.58e-06	0.000108	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—CXCL8—breast cancer	7.55e-06	0.000107	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PPARGC1B—breast cancer	7.53e-06	0.000107	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—ERBB3—breast cancer	7.5e-06	0.000106	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—FGFR2—breast cancer	7.49e-06	0.000106	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP17A1—breast cancer	7.42e-06	0.000105	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—SMAD4—breast cancer	7.38e-06	0.000105	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PTGS1—breast cancer	7.35e-06	0.000104	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ENO1—breast cancer	7.35e-06	0.000104	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IGF1R—breast cancer	7.33e-06	0.000104	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—CXCL8—breast cancer	7.3e-06	0.000104	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—IL2—breast cancer	7.21e-06	0.000102	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—HES1—breast cancer	7.2e-06	0.000102	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TERT—breast cancer	7.19e-06	0.000102	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PTEN—breast cancer	7.19e-06	0.000102	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PLA2G4A—breast cancer	7.16e-06	0.000102	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—NCOR1—breast cancer	7.16e-06	0.000102	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CA9—breast cancer	7.11e-06	0.000101	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTA4—breast cancer	7.11e-06	0.000101	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CSF2—breast cancer	7.08e-06	0.000101	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—FGF1—breast cancer	7.08e-06	0.000101	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—NCOA2—breast cancer	7.07e-06	0.0001	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—RAF1—breast cancer	7.06e-06	0.0001	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—NRG1—breast cancer	7.03e-06	9.98e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—FGFR1—breast cancer	6.98e-06	9.91e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—H2AFX—breast cancer	6.98e-06	9.91e-05	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—IL2—breast cancer	6.98e-06	9.9e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTA2—breast cancer	6.93e-06	9.84e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GPX2—breast cancer	6.93e-06	9.84e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—E2F1—breast cancer	6.93e-06	9.84e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—PIK3CB—breast cancer	6.9e-06	9.79e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—HIF1A—breast cancer	6.87e-06	9.76e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—FASN—breast cancer	6.86e-06	9.74e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—SULT1A1—breast cancer	6.85e-06	9.72e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GPX4—breast cancer	6.85e-06	9.72e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—BCHE—breast cancer	6.83e-06	9.7e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—SLC5A5—breast cancer	6.75e-06	9.58e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—LEP—breast cancer	6.71e-06	9.53e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—IDH1—breast cancer	6.69e-06	9.5e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTA1—breast cancer	6.69e-06	9.5e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—SPP1—breast cancer	6.66e-06	9.45e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CAV1—breast cancer	6.65e-06	9.44e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—CXCL8—breast cancer	6.63e-06	9.41e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—NAT2—breast cancer	6.61e-06	9.39e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ERBB3—breast cancer	6.58e-06	9.35e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—FGFR2—breast cancer	6.57e-06	9.34e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—KDR—breast cancer	6.57e-06	9.34e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—SLC2A1—breast cancer	6.52e-06	9.26e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—NQO1—breast cancer	6.52e-06	9.26e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—ESR1—breast cancer	6.41e-06	9.1e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP3A4—breast cancer	6.36e-06	9.03e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—IL2—breast cancer	6.33e-06	8.99e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—FN1—breast cancer	6.33e-06	8.99e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TERT—breast cancer	6.31e-06	8.96e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—NFKBIA—breast cancer	6.25e-06	8.88e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP1B1—breast cancer	6.25e-06	8.87e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—NOTCH1—breast cancer	6.19e-06	8.79e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—HSP90AA1—breast cancer	6.13e-06	8.7e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—FGFR1—breast cancer	6.13e-06	8.7e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PIK3CG—breast cancer	6.06e-06	8.6e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—KIT—breast cancer	6.06e-06	8.6e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—APC—breast cancer	6.06e-06	8.6e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—HIF1A—breast cancer	6.04e-06	8.57e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—EGF—breast cancer	5.99e-06	8.5e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—NCOA1—breast cancer	5.96e-06	8.46e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—LEP—breast cancer	5.89e-06	8.37e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—STK11—breast cancer	5.88e-06	8.34e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP19A1—breast cancer	5.88e-06	8.34e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CAV1—breast cancer	5.84e-06	8.29e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—MAPK3—breast cancer	5.8e-06	8.24e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—DPYD—breast cancer	5.8e-06	8.23e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—MED12—breast cancer	5.8e-06	8.23e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—KDR—breast cancer	5.77e-06	8.2e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ALDOA—breast cancer	5.71e-06	8.11e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—BRAF—breast cancer	5.69e-06	8.08e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ESR1—breast cancer	5.63e-06	7.99e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—FN1—breast cancer	5.56e-06	7.89e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IGF1—breast cancer	5.54e-06	7.87e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—NCOA3—breast cancer	5.54e-06	7.87e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—AKT2—breast cancer	5.54e-06	7.87e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—EGFR—breast cancer	5.52e-06	7.83e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—SLC2A2—breast cancer	5.5e-06	7.81e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—NFKBIA—breast cancer	5.49e-06	7.8e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—COMT—breast cancer	5.46e-06	7.76e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—NOTCH1—breast cancer	5.44e-06	7.72e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GSTP1—breast cancer	5.44e-06	7.72e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—MTR—breast cancer	5.39e-06	7.65e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CPT1A—breast cancer	5.39e-06	7.65e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ABCG2—breast cancer	5.39e-06	7.65e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—HMOX1—breast cancer	5.36e-06	7.61e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ITPR1—breast cancer	5.35e-06	7.6e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PIK3CD—breast cancer	5.32e-06	7.56e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—APC—breast cancer	5.32e-06	7.55e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PIK3CG—breast cancer	5.32e-06	7.55e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—KIT—breast cancer	5.32e-06	7.55e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—HPGDS—breast cancer	5.29e-06	7.51e-05	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—PIK3CA—breast cancer	5.27e-06	7.49e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—SERPINE1—breast cancer	5.27e-06	7.48e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—EGF—breast cancer	5.26e-06	7.46e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—HBA1—breast cancer	5.25e-06	7.46e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—KRAS—breast cancer	5.21e-06	7.4e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ABCB1—breast cancer	5.15e-06	7.31e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTT1—breast cancer	5.13e-06	7.28e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ACHE—breast cancer	5.13e-06	7.28e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—MAPK3—breast cancer	5.09e-06	7.23e-05	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PIK3CA—breast cancer	5.07e-06	7.2e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—TYMS—breast cancer	5.05e-06	7.18e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—NOS3—breast cancer	5.03e-06	7.14e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—BRAF—breast cancer	5e-06	7.1e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—NCOR1—breast cancer	5e-06	7.09e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PLA2G4A—breast cancer	5e-06	7.09e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GSTM1—breast cancer	5e-06	7.09e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IGF1—breast cancer	4.87e-06	6.91e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—AKT2—breast cancer	4.86e-06	6.91e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP17A1—breast cancer	4.85e-06	6.89e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—EGFR—breast cancer	4.84e-06	6.88e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PTGS1—breast cancer	4.8e-06	6.82e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ENO1—breast cancer	4.8e-06	6.82e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—PIK3CA—breast cancer	4.79e-06	6.8e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GPX1—breast cancer	4.78e-06	6.79e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MDM2—breast cancer	4.77e-06	6.77e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—RAF1—breast cancer	4.75e-06	6.75e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP1A1—breast cancer	4.74e-06	6.72e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—RELA—breast cancer	4.73e-06	6.72e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP2D6—breast cancer	4.71e-06	6.69e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—ERBB2—breast cancer	4.7e-06	6.68e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ERCC2—breast cancer	4.7e-06	6.67e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PIK3CD—breast cancer	4.67e-06	6.64e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MTOR—breast cancer	4.64e-06	6.59e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PIK3CB—breast cancer	4.64e-06	6.59e-05	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—PIK3CA—breast cancer	4.63e-06	6.57e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—NCOA2—breast cancer	4.63e-06	6.57e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—SERPINE1—breast cancer	4.62e-06	6.56e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—KRAS—breast cancer	4.58e-06	6.5e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—FASN—breast cancer	4.49e-06	6.37e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—BCHE—breast cancer	4.47e-06	6.34e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CXCL8—breast cancer	4.46e-06	6.33e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—HRAS—breast cancer	4.43e-06	6.29e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—MTHFR—breast cancer	4.41e-06	6.27e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—NOS3—breast cancer	4.41e-06	6.27e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—SLC5A5—breast cancer	4.41e-06	6.27e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CDKN1B—breast cancer	4.35e-06	6.18e-05	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—AKT1—breast cancer	4.31e-06	6.12e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CASP3—breast cancer	4.27e-06	6.06e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IL2—breast cancer	4.26e-06	6.05e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—SLC2A1—breast cancer	4.26e-06	6.05e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—NQO1—breast cancer	4.26e-06	6.05e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—IL6—breast cancer	4.24e-06	6.02e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—PIK3CA—breast cancer	4.2e-06	5.97e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MDM2—breast cancer	4.19e-06	5.95e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—RAF1—breast cancer	4.17e-06	5.93e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—RELA—breast cancer	4.15e-06	5.9e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CCND1—breast cancer	4.15e-06	5.9e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—JUN—breast cancer	4.15e-06	5.89e-05	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—AKT1—breast cancer	4.14e-06	5.88e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ERBB2—breast cancer	4.13e-06	5.86e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CTNNB1—breast cancer	4.11e-06	5.84e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP1B1—breast cancer	4.09e-06	5.8e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PIK3CB—breast cancer	4.07e-06	5.79e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MTOR—breast cancer	4.07e-06	5.79e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CAV1—breast cancer	4.07e-06	5.78e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MMP9—breast cancer	4.03e-06	5.73e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CDKN1A—breast cancer	4.02e-06	5.71e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PTEN—breast cancer	4.01e-06	5.69e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—HSP90AA1—breast cancer	4.01e-06	5.69e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MAPK8—breast cancer	3.92e-06	5.57e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CXCL8—breast cancer	3.92e-06	5.56e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—AKT1—breast cancer	3.91e-06	5.55e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—NCOA1—breast cancer	3.9e-06	5.53e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—HRAS—breast cancer	3.89e-06	5.52e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—STK11—breast cancer	3.84e-06	5.45e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP19A1—breast cancer	3.84e-06	5.45e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CDKN1B—breast cancer	3.82e-06	5.43e-05	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—AKT1—breast cancer	3.78e-06	5.37e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CASP3—breast cancer	3.75e-06	5.32e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IL2—breast cancer	3.74e-06	5.31e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—IL6—breast cancer	3.72e-06	5.29e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—SRC—breast cancer	3.72e-06	5.28e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PIK3CG—breast cancer	3.71e-06	5.27e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CCND1—breast cancer	3.65e-06	5.18e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—JUN—breast cancer	3.64e-06	5.17e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—VEGFA—breast cancer	3.62e-06	5.14e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CTNNB1—breast cancer	3.61e-06	5.13e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—STAT3—breast cancer	3.59e-06	5.09e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—COMT—breast cancer	3.57e-06	5.07e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTP1—breast cancer	3.55e-06	5.05e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MMP9—breast cancer	3.54e-06	5.03e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CDKN1A—breast cancer	3.53e-06	5.01e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PTEN—breast cancer	3.52e-06	5e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—HMOX1—breast cancer	3.51e-06	4.98e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ITPR1—breast cancer	3.5e-06	4.97e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MAPK8—breast cancer	3.44e-06	4.89e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—AKT1—breast cancer	3.43e-06	4.88e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MAPK3—breast cancer	3.43e-06	4.87e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ABCB1—breast cancer	3.36e-06	4.78e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MYC—breast cancer	3.33e-06	4.73e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TGFB1—breast cancer	3.32e-06	4.72e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—TYMS—breast cancer	3.3e-06	4.69e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—NCOR1—breast cancer	3.27e-06	4.64e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTM1—breast cancer	3.27e-06	4.64e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PLA2G4A—breast cancer	3.27e-06	4.64e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—SRC—breast cancer	3.26e-06	4.64e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PIK3CD—breast cancer	3.26e-06	4.63e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—EGFR—breast cancer	3.26e-06	4.63e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ALB—breast cancer	3.22e-06	4.57e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—VEGFA—breast cancer	3.18e-06	4.52e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—STAT3—breast cancer	3.15e-06	4.47e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GPX1—breast cancer	3.13e-06	4.44e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP1A1—breast cancer	3.1e-06	4.4e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—NOS3—breast cancer	3.08e-06	4.37e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—KRAS—breast cancer	3.08e-06	4.37e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ERCC2—breast cancer	3.07e-06	4.36e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MAPK3—breast cancer	3.01e-06	4.27e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MYC—breast cancer	2.93e-06	4.15e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TGFB1—breast cancer	2.92e-06	4.14e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—MTHFR—breast cancer	2.89e-06	4.1e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—EGFR—breast cancer	2.86e-06	4.06e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PIK3CB—breast cancer	2.84e-06	4.04e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PIK3CA—breast cancer	2.83e-06	4.02e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PTGS2—breast cancer	2.82e-06	4e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TP53—breast cancer	2.74e-06	3.89e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—KRAS—breast cancer	2.7e-06	3.84e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CAV1—breast cancer	2.66e-06	3.78e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—HRAS—breast cancer	2.62e-06	3.72e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IL6—breast cancer	2.5e-06	3.56e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PIK3CA—breast cancer	2.48e-06	3.53e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PTEN—breast cancer	2.46e-06	3.49e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PIK3CG—breast cancer	2.43e-06	3.44e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TP53—breast cancer	2.4e-06	3.41e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—AKT1—breast cancer	2.31e-06	3.28e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—HRAS—breast cancer	2.3e-06	3.26e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IL6—breast cancer	2.2e-06	3.12e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PIK3CD—breast cancer	2.13e-06	3.03e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ALB—breast cancer	2.1e-06	2.99e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—AKT1—breast cancer	2.03e-06	2.88e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—NOS3—breast cancer	2.01e-06	2.86e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PIK3CB—breast cancer	1.86e-06	2.64e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PTGS2—breast cancer	1.84e-06	2.61e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PIK3CA—breast cancer	1.73e-06	2.46e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PTEN—breast cancer	1.61e-06	2.28e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—AKT1—breast cancer	1.42e-06	2.01e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PIK3CA—breast cancer	1.13e-06	1.61e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—AKT1—breast cancer	9.25e-07	1.31e-05	CbGpPWpGaD
